Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abingdon HealthABDXF -1.20%49 3-Year EBITDA Growth Rate is 51.00% as of Dec. 2025, which is 3% above its 10-year median of 49.30. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Abingdon Health ranks better than 85.63% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 51.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Abingdon Health was 51.00% per year. The lowest was -83.50% per year. And the median was 49.30% per year.
Abingdon Health (OTCPK:ABDXF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Abingdon Health 3-Year EBITDA Growth Rate Related Terms
ABDXF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Abingdon Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Abingdon Health's 3-Year EBITDA Growth Rate falls into.
Abingdon Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 51.00% mean?
Abingdon Health (ABDXF) has a 3-Year EBITDA Growth Rate of 51.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Abingdon Health and its competitors. This is near median its historical median of 49.30. According to the industry distribution chart, Abingdon Health ranks #24 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 14.4%.
Is Abingdon Health's 3-Year EBITDA Growth Rate too high?
Abingdon Health's current 3-Year EBITDA Growth Rate of 51.00% is near median its 10-year median of 49.30. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Abingdon Health's value of 51.00% is 363.6% above this industry median. Based on the distribution chart, Abingdon Health ranks #24 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #24 out of 167 companies for 3-Year EBITDA Growth Rate. This places Abingdon Health in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.00. Abingdon Health's value of 51.00% is 363.6% above this benchmark. While the company's 10-year median is 49.30 vs. the industry median of 11.00, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current 3-Year EBITDA Growth Rate of 51.00% is 363.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current 3-Year EBITDA Growth Rate is 51.00%, which is near median its own 10-year median of 49.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.13 — trading 38.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 51.00%, which is near median its 10-year median of 49.30 and 363.6% above the Medical Diagnostics & Research industry median of 11.00. Abingdon Health's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current 3-Year EBITDA Growth Rate is 51.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.13 is trading 38.1% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
3-Year EBITDA Growth Rate: 51.00% (near median its 10-year median of 49.30)
GF Value™: $0.21 vs. price of $0.13 (38.1% below fair value)
Industry Position: 363.6% above the Medical Diagnostics & Research median (#24 of 167)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
